Vitality Biopharma (OTCQB:VBIO) announced the publication of an international PCT patent application that covers a new class of cannabinoid pharmaceuticals.
As quoted in the press release:
The publication of the international patent filing is the first public disclosure of its full content, which includes 79 patent claims and almost 200 individual compounds. Novel cannabinoid prodrugs are described for the most common phytocannabinoids, THC, cannabidiol (CBD), and CBDV, as well as a variety of other phytocannabinoids and endocannabinoids. The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide. Coverage of any underlying patent claims would extend to 2035 in the United States, and may be subject to patent term extensions that would extend this patent protection. The full text may be accessed online: “https://patentscope.wipo.int/search/docservicepdf_pct/id00000037217335/PDOC/WO2017053574.pdf“.
In addition, the Company has filed for intellectual property coverage for methods to treat dysbiosis, gastrointestinal infections, and other digestive disorders using cannabinoids. The Company’s prodrug technology enables large concentrations of cannabinoids to be selectively delivered to the intestinal tract and avoids psychoactivity, making them well suited for treatment of pediatric conditions.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
The product will include polyphenols known to have significant health benefits.